KAR 5585

Drug Profile

KAR 5585

Alternative Names: KAR5585

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Karos Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pulmonary arterial hypertension
  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 17 Aug 2016 Karos Pharmaceuticals plans a phase II trial for Malignant carcinoid syndrome in 2017 in the USA
  • 17 Aug 2016 Karos Pharmaceuticals has patent protection for KAR 5585 in USA
  • 01 Aug 2016 Karos Pharmaceuticals completes a phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in USA (PO) (NCT02746237)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top